Annexon Biosciences

APLS

This biopharmaceutical company develops complement-based therapies to treat autoimmune and inflammatory diseases for patients with conditions like paroxysmal nocturnal haemoglobinuria and geographic atrophy.

Aviceda

This biotechnology company develops nanoparticle glyco-therapeutics for patients with immune-mediated diseases, primarily targeting macular degeneration and other ophthalmic, neurological and inflammatory conditions.

True North Therapeutics

This biotechnology company develops monoclonal antibodies targeting the complement system to treat patients with rare blood, kidney and skin diseases.

ONL Therapeutics

This biopharmaceutical company develops neuroprotective peptide therapies to prevent retinal cell death and preserve vision for patients with retinal diseases and conditions.

Biohaven

This biopharmaceutical company develops therapeutics for patients with debilitating neurological, neuroinflammatory, and metabolic diseases, as well as immunological and oncology disorders.

Iolyx Therapeutics

The company develops immunomodulatory medicines to treat ocular inflammation and autoimmune eye diseases for patients worldwide.

MindImmune Therapeutics

This company develops monoclonal antibody therapeutics to treat neurodegenerative diseases and neuroinflammation for patients with central nervous system disorders.

Seranova Bio

This biotechnology company develops autoantibody-based therapeutics and discovery platforms for pharmaceutical partners and clinicians treating autoimmune diseases, cancer and neurodegenerative disorders.